2026-04-03 20:07:32
VivoSim Labs, Inc. Prices $4 Million Public Offering with Initial Closing of $3 Million
Expected Stock impact: Slightly Positive
VivoSim Labs, Inc. (Nasdaq: VIVS), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, has announced the pricing of a public offering expected to raise up to $4 million. The offering consists of two tranches, with the initial tranche closing on April 1, 2026, raising $3 million. This tranche includes the issuance of 286,557 shares of common stock at a price of $1.14 per share, along with 2,345,022 pre-funded warrants priced at $1.139 each. Each share of common stock is accompanied by 1.5 common warrants, which have an exercise price of $1.71 per share. The second tranche, contingent on certain conditions, may raise an additional $1 million, allowing purchasers from the initial tranche to buy more shares or pre-funded warrants. The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including research and development, regulatory affairs, and potential acquisitions. The offering is being managed by Joseph Gunnar & Co., LLC as the exclusive placement agent.
